Lupin Pharmaceuticals, Inc. Receives FDA Approval for Imipramine Pamoate Capsules

BALTIMORE, April 20 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths. Commercial shipments of the product have already commenced.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

For the financial year ended March 2009, Lupin's Consolidated Revenues and Profit after Tax were Rs.39,145 million (US$ 851 million) and Rs. 5015 million (US$ 109 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

*Tofranil-PM(R) is a registered trademark of Mallinckrodt Inc.

CONTACT: Edith St-Hilaire, Director of Marketing of Lupin Pharmaceuticals,
+1-410-576-2000, Ext. 207, esthilaire@lupinusa.com

Web site: http://www.lupinpharmaceuticals.com/